<DOC>
	<DOCNO>NCT02797132</DOCNO>
	<brief_summary>This Phase 3 , 2-part ( Part A Part B ) , open-label , multicenter study evaluate pharmacokinetics ( PK ) , safety , tolerability , pharmacodynamics ( PD ) multiple dos Lumacaftor/Ivacaftor ( LUM/IVA ) subject 2 5 year age ( inclusive ) Cystic Fibrosis ( CF ) , homozygous F508del . Subjects participate Part A may participate Part B , patient meet eligibility criterion .</brief_summary>
	<brief_title>Safety Pharmacokinetic Study Lumacaftor/Ivacaftor Subjects Aged 2 Through 5 Years With Cystic Fibrosis , Homozygous F508del</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>Subjects weigh ≥8 kilogram ( kg ) without shoe wear light clothe Screening Visit Subjects confirm diagnosis CF Screening Visit Subjects homozygous F508del Cystic fibrosis transmembrane conductance regulator ( CFTR ) mutation Subjects ppFEV1 ≥40 adjust age , sex , height ethnicity Any clinically significant laboratory abnormality Screening Visit would interfere study assessment pose undue risk subject An acute upper low respiratory infection , pulmonary exacerbation , change therapy ( include antibiotic ) pulmonary disease within 28 day Day 1 A standard 12 lead ECG demonstrate QTc &gt; 450 millisecond ( msec ) Screening Visit . History solid organ hematological transplantation . Ongoing prior participation investigational drug study ( include study investigate LUM and/or IVA ) within 30 day Screening Visit . History cataract/lens opacity evidence cataract/lens opacity determine clinically significant licensed ophthalmologist ophthalmologic examination Screening Visit</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>5 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>CF</keyword>
</DOC>